ATHENS, Ga. and LOS GATOS, Calif., May 31, 2023 /PRNewswire/ -- Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company harnessing the full breadth of the immune system to protect against serious infectious diseases, announced today that company CEO Biao He, Ph.D., will present and host one-on-one partnering meetings at the 2023 Biotechnology Innovation Organization International Convention being held June 5-8, 2023 at the Boston Convention and Exhibition Center in Boston, Massachusetts.
The company presentation will take place at 2:30 PM Eastern in Room 104B on Monday, June 5. Partnering meetings can be scheduled using BIO's One-on-One Partnering™ system.
In addition to the company presentation, Dr. He will speak on a panel entitled "New Tools in the Infectious Disease Toolbox: Combatting Future Biological Threats" on Wednesday, June 7 from 4:15 PM to 5:15 PM in Session Room 208. Additional panelists include
About Blue Lake Biotechnology
Blue Lake Biotechnology, Inc. and its affiliate, CyanVac LLC, are developing intranasal vaccines that harness the full breadth of the immune system to keep people healthy, prevent serious infectious diseases, and protect the health of vulnerable populations. Our platform uses a proprietary parainfluenza virus 5 vector into which a foreign gene from a targeted pathogen is inserted. We have generated a robust clinical-stage pipeline of best-in-class vaccines designed to overcome the limitations of existing vaccine technologies. Our lead product candidates have demonstrated potential for high efficacy and lasting durability with few vaccine-related side effects.
Learn more at https://www.bluelakebiotechnology.com.
CONTACTS:
Carolyn Hawley
Evoke Canale
carolyn.hawley@evokegroup.com
619-849-5382
Samuel Wu, Chief Business Officer
Blue Lake Biotechnology, Inc. and CyanVac LLC
swu@bluelakebiotechnology.com
650-427-0166
SOURCE Blue Lake Biotechnology, Inc.